NO20080408L - Azaindazolforbindelser og anvendelse derav - Google Patents

Azaindazolforbindelser og anvendelse derav

Info

Publication number
NO20080408L
NO20080408L NO20080408A NO20080408A NO20080408L NO 20080408 L NO20080408 L NO 20080408L NO 20080408 A NO20080408 A NO 20080408A NO 20080408 A NO20080408 A NO 20080408A NO 20080408 L NO20080408 L NO 20080408L
Authority
NO
Norway
Prior art keywords
compounds
ccr1
antagonists
azaindazole compounds
assays
Prior art date
Application number
NO20080408A
Other languages
English (en)
Other versions
NO340621B1 (no
Inventor
Penglie Zhang
Andrew M K Penneli
John J Kim Wright
Wei Chen
Manmohan R Leleti
Yandong Li
Lianfa Li
Yuan Xu
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37595833&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20080408(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of NO20080408L publication Critical patent/NO20080408L/no
Publication of NO340621B1 publication Critical patent/NO340621B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)

Abstract

Det er tilveiebrakt forbindelser som virker som potente antagonister av CCR1-reseptorer, og som har antiinflammatorisk aktivitet in vivo. Forbindelsene er generelt arylpiperazinderivater med formel Ia/Ib og er nyttige i farmasøytiske preparater, metoder for behandling av CCR1-medierte sykdommer og som kontroller i analyser for identifisering av kompetitive CCR1-antagonister.
NO20080408A 2005-06-22 2008-01-21 Azaindazolforbindelser, farmasøytiske preparater derav og anvendelse derav NO340621B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69352505P 2005-06-22 2005-06-22
PCT/US2006/024313 WO2007002293A2 (en) 2005-06-22 2006-06-22 Azaindazole compounds and methods of use

Publications (2)

Publication Number Publication Date
NO20080408L true NO20080408L (no) 2008-03-25
NO340621B1 NO340621B1 (no) 2017-05-15

Family

ID=37595833

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080408A NO340621B1 (no) 2005-06-22 2008-01-21 Azaindazolforbindelser, farmasøytiske preparater derav og anvendelse derav

Country Status (26)

Country Link
US (2) US7524845B2 (no)
EP (1) EP1906965B1 (no)
JP (1) JP5275794B2 (no)
KR (2) KR20140026644A (no)
CN (1) CN101242839B (no)
AU (1) AU2006262122B2 (no)
BR (1) BRPI0612112A8 (no)
CA (1) CA2612552C (no)
DK (1) DK1906965T3 (no)
EA (1) EA017278B9 (no)
ES (1) ES2543714T3 (no)
HR (1) HRP20150832T1 (no)
HU (1) HUE025476T2 (no)
IL (1) IL188050A (no)
MA (1) MA29568B1 (no)
MX (1) MX2007015917A (no)
NO (1) NO340621B1 (no)
NZ (1) NZ564258A (no)
PL (1) PL1906965T3 (no)
PT (1) PT1906965E (no)
RS (1) RS54206B1 (no)
SG (2) SG162807A1 (no)
SI (1) SI1906965T1 (no)
UA (1) UA95777C2 (no)
WO (2) WO2007002293A2 (no)
ZA (2) ZA200800309B (no)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1831225A2 (en) 2004-11-19 2007-09-12 The Regents of the University of California Anti-inflammatory pyrazolopyrimidines
ZA200800309B (en) 2005-06-22 2009-10-28 Chemocentryx Inc Azaindazole compounds and methods of use
US7777035B2 (en) * 2005-06-22 2010-08-17 Chemocentryx, Inc. Azaindazole compounds and methods of use
EA200870409A1 (ru) 2006-04-04 2009-04-28 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Антагонисты киназы pi3
US20090252779A1 (en) * 2006-06-22 2009-10-08 Chemocentryx, Inc. Azaindazole compounds and methods of use
NZ581405A (en) * 2007-05-22 2011-06-30 Chemocentryx Inc 3-(Imidazolyl)-pyrazolo[3,4-b]pyridines and their use in treating CCR1-mediated disorders
GB2467670B (en) 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
CA2711558C (en) 2008-01-04 2016-12-13 Intellikine, Inc. Phosphatidyl inositol-3 kinase inhibiting compounds
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
JP5547099B2 (ja) 2008-03-14 2014-07-09 インテリカイン， エルエルシー キナーゼ阻害剤および使用方法
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
EP2285783B1 (en) 2008-04-29 2014-05-21 Boehringer Ingelheim International GmbH Indazole compounds as ccr1 receptor antagonists
WO2009137338A1 (en) 2008-05-06 2009-11-12 Boehringer Ingelheim International Gmbh Pyrazole compounds as ccr1 antagonists
AU2009268611B2 (en) 2008-07-08 2015-04-09 Intellikine, Llc Kinase inhibitors and methods of use
WO2010006072A2 (en) 2008-07-08 2010-01-14 The Regents Of The University Of California Mtor modulators and uses thereof
MX2011002636A (es) 2008-09-11 2011-04-05 Chemocentryx Inc 4-amino-3-(imidazoil)-pirazolo[3,4-d]pirimidinas.
JP5507567B2 (ja) 2008-09-26 2014-05-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ１受容体拮抗薬としてのアザインダゾール化合物
JP5731978B2 (ja) 2008-09-26 2015-06-10 インテリカイン， エルエルシー 複素環キナーゼ阻害剤
CA2740885C (en) 2008-10-16 2018-04-03 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
WO2010051561A1 (en) * 2008-11-03 2010-05-06 Chemocentryx, Inc. Compounds for the treatment of osteoporosis and cancers
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
JP5807971B2 (ja) * 2009-04-27 2015-11-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｘｃｒ３受容体アンタゴニスト
US8362249B2 (en) * 2009-04-27 2013-01-29 Boehringer Ingelheim International Gmbh CXCR3 receptor antagonists
EP2427195B1 (en) 2009-05-07 2019-05-01 Intellikine, LLC Heterocyclic compounds and uses thereof
SG176885A1 (en) * 2009-08-03 2012-01-30 Acraf Process for the preparation of 1-benzyl-3-hydr0xymethyl-1h-indaz0le and its derivatives and required magnesium intermediates
WO2011047384A2 (en) 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
PL2491028T3 (pl) * 2009-10-21 2014-05-30 Boehringer Ingelheim Int Związki indazolowe i pirazolopirydynowe jako antagoniści receptora CCR1
US8927550B2 (en) 2009-10-27 2015-01-06 Boehringer Ingelheim International Gmbh Heterocyclic compounds as CCR1 receptor antagonists
GB201004311D0 (en) 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
JP5793182B2 (ja) 2010-04-30 2015-10-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ１受容体アンタゴニストとしてのアザインダゾールアミド化合物
AU2011255218B2 (en) 2010-05-21 2015-03-12 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環化合物及びその使用
HUE032405T2 (en) 2010-12-20 2017-09-28 Pfizer New condensed pyridine compounds as casein kinase inhibitors
US8546442B2 (en) 2010-12-23 2013-10-01 Boehringer Ingelheim International Gmbh Pyrazolopiperidine compounds as CCR1 receptor antagonists
AU2012205669B2 (en) 2011-01-10 2015-08-20 Infinity Pharmaceuticals Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
GB2488752A (en) * 2011-02-21 2012-09-12 Sony Dadc Austria Ag Microfluidic Device
JP6130305B2 (ja) 2011-02-23 2017-05-17 インテリカイン， エルエルシー キナーゼ阻害剤の組み合わせおよびそれらの使用
US9056877B2 (en) 2011-07-19 2015-06-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP6027610B2 (ja) 2011-07-19 2016-11-16 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環式化合物及びその使用
EP2751093A1 (en) 2011-08-29 2014-07-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX370814B (es) 2011-09-02 2020-01-08 Univ California Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
GB201115853D0 (en) * 2011-09-14 2011-10-26 Proximagen Ltd New enzyme inhibitor compounds
US9150574B2 (en) 2011-09-14 2015-10-06 Proximagen Limited Enzyme inhibitor compounds
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
MX2015003874A (es) 2012-09-26 2015-12-16 Univ California Modulacion de ire1.
KR102229478B1 (ko) 2012-11-01 2021-03-18 인피니티 파마슈티칼스, 인코포레이티드 Pi3 키나아제 동형단백질 조절인자를 사용하는 암의 치료
AU2013355054B2 (en) * 2012-12-07 2017-08-24 Chemocentryx, Inc. Diazole lactams
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
SG11201600504TA (en) 2013-07-22 2016-02-26 Actelion Pharmaceuticals Ltd 1-(piperazin-1-yl)-2-([1,2,4]triazol-1-yl)-ethanone derivatives
PE20160685A1 (es) 2013-10-04 2016-07-23 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
SG10201808053XA (en) 2014-03-19 2018-10-30 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
CN105801574A (zh) * 2014-12-31 2016-07-27 上海药谷药业有限公司 一种1H-吡唑并[3,4-b]吡啶化合物的制备方法
TWI693221B (zh) 2015-01-15 2020-05-11 瑞士商愛杜西亞製藥有限公司 作為ｃｘｃｒ３受體調節劑之羥烷基六氫吡衍生物
AR103399A1 (es) 2015-01-15 2017-05-10 Actelion Pharmaceuticals Ltd Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
IL261998B2 (en) * 2016-04-07 2023-03-01 Chemocentryx Inc Reducing your burden by giving ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX391135B (es) 2016-06-24 2025-03-21 Infinity Pharmaceuticals Inc Terapias de combinacion.
US12448374B2 (en) 2018-06-07 2025-10-21 Disarm Therapeutics, Inc. Inhibitors of SARM1
CN108570049A (zh) * 2018-07-24 2018-09-25 上海毕得医药科技有限公司 一种6-氯-1氢-吡唑并[3,4-b]吡啶的合成方法
CN108794470B (zh) * 2018-07-25 2020-06-26 上海毕得医药科技有限公司 一种6-肼基-1H-吡唑并[3,4-b]吡啶及其下游产品的合成方法
CN113164508B (zh) 2018-12-19 2025-07-08 达萨玛治疗公司 与神经保护剂组合的sarm1抑制剂
PH12021552839A1 (en) * 2019-06-14 2022-10-03 Janssen Pharmaceutica Nv Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators
CN110343103A (zh) * 2019-07-04 2019-10-18 深圳市格物致欣化学技术有限公司 吡唑并吡啶类化合物及其制备方法
US11872217B2 (en) 2019-07-10 2024-01-16 Chemocentryx, Inc. Indanes as PD-L1 inhibitors
CR20220216A (es) 2019-10-16 2023-01-09 Chemocentryx Inc Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
US11713307B2 (en) 2019-10-16 2023-08-01 Chemocentryx, Inc. Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases
AR129722A1 (es) * 2022-06-28 2024-09-18 Arcus Biosciences Inc Compuestos inhibidores de axl

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4238497A (en) * 1977-10-26 1980-12-09 Burroughs Wellcome Co. Imidazoline derivatives, salts thereof and their use as pesticides
AU518569B2 (en) * 1979-08-07 1981-10-08 Farmos-Yhtyma Oy 4-benzyl- and 4-benzoyl imidazole derivatives
US4927942A (en) * 1988-12-15 1990-05-22 Texaco Chemical Co. Method for the preparation of imidazoles
RU2317988C2 (ru) * 2000-08-14 2008-02-27 Орто-Макнейл Фармасьютикал, Инк. Замещенные пиразолы, фармацевтическая композиция на их основе, применение фармацевтической композиции и способ ингибирования активности катепсина s
RU2286343C2 (ru) * 2001-08-10 2006-10-27 Орто-Макнейл Фармасьютикал, Инк. Замещенные пиразолы
CZ2004519A3 (cs) * 2001-10-22 2004-12-15 Pfizer Products Inc. Deriváty piperazinu s účinky antagonisty receptoru CCR1
US20050256130A1 (en) * 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
MXPA04012393A (es) * 2002-06-12 2005-06-17 Chemocentryx Derivados de piperazina 1-aril-4-substituidos para utilizar como antagonistas ccr1 para tratamiento de inflamacion y desordenes inmunes.
US7842693B2 (en) * 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
US7589199B2 (en) * 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
US7435831B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
CN1950082B (zh) * 2004-03-03 2013-02-06 凯莫森特里克斯股份有限公司 双环和桥连的含氮杂环化物
ZA200800309B (en) 2005-06-22 2009-10-28 Chemocentryx Inc Azaindazole compounds and methods of use

Also Published As

Publication number Publication date
JP2008546794A (ja) 2008-12-25
EP1906965B1 (en) 2015-05-06
KR20140026644A (ko) 2014-03-05
HUE025476T2 (en) 2016-02-29
US20070010523A1 (en) 2007-01-11
IL188050A (en) 2015-10-29
WO2007002293A2 (en) 2007-01-04
US7524845B2 (en) 2009-04-28
CN101242839A (zh) 2008-08-13
DK1906965T3 (en) 2015-08-03
NZ564258A (en) 2011-02-25
HK1124241A1 (en) 2009-07-10
HRP20150832T1 (hr) 2015-09-25
AU2006262122B2 (en) 2013-01-17
NO340621B1 (no) 2017-05-15
BRPI0612112A8 (pt) 2017-12-26
IL188050A0 (en) 2008-03-20
ES2543714T3 (es) 2015-08-21
KR20080039850A (ko) 2008-05-07
SG162807A1 (en) 2010-07-29
EA017278B1 (ru) 2012-11-30
PT1906965E (pt) 2015-09-03
WO2007002293A3 (en) 2007-03-08
CA2612552C (en) 2015-03-24
CA2612552A1 (en) 2007-01-04
PL1906965T3 (pl) 2015-10-30
WO2007002667A3 (en) 2007-05-10
RS54206B1 (sr) 2015-12-31
WO2007002667A2 (en) 2007-01-04
ZA200800309B (en) 2009-10-28
CN101242839B (zh) 2012-11-07
EP1906965A4 (en) 2011-05-18
EA200800100A1 (ru) 2008-06-30
AU2006262122A1 (en) 2007-01-04
UA95777C2 (en) 2011-09-12
KR101418024B1 (ko) 2014-07-16
MX2007015917A (es) 2008-03-10
EP1906965A2 (en) 2008-04-09
ZA200901845B (en) 2011-03-30
MA29568B1 (fr) 2008-06-02
SI1906965T1 (sl) 2015-09-30
JP5275794B2 (ja) 2013-08-28
EA017278B9 (ru) 2013-01-30
SG10201504801VA (en) 2015-07-30
BRPI0612112A2 (pt) 2010-10-19
US20070010524A1 (en) 2007-01-11

Similar Documents

Publication Publication Date Title
EA017278B9 (ru) Соединения азаиндазола и способы применения
EP2155203A4 (en) Azaindazole compounds and methods of use
DK2324008T3 (da) Diarylpyrazol som protein kinase inhibitorer
ATE514699T1 (de) Substituierte pyrrolopyrazolderivate als kinaseinhibitoren
NO20091893L (no) Nye 1,4-benzotiepin-1,1-dioksidderivater som er substituert med benzylgrupper, fremgangsmater for fremstilling av medisiner inneholdende forbindelsene og anvendelse derav.
NO20071246L (no) Kinazolinonderivater og deres anvendelse som B-RAF-inhibitorer.
BRPI0515489A (pt) derivados heterocìclicos e sua utilização como inibidores de estearoil-coa desaturase
NO20083427L (no) Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
WO2007022257A3 (en) Monocyclic and bicyclic compounds and methods of use
EA200800564A1 (ru) Производные ксантина как селективные агонисты нм74а
BRPI0418939A (pt) derivados de nicotinamida e sua utilização como agentes terapêuticos
WO2007044804A3 (en) Piperidine derivatives and methods of use
NO20044731L (no) Kinolin- og isokinolinderivater fremgangsmate for fremstilling derav og anvendelse derav som betennelseshemmere
NO20080670L (no) Substituerte piperaziner som metabotrofiske glutamatreseptorantagonister
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
AR066701A1 (es) 3-( imidazolil)- pirazolo {3,4-b] piridinas, composicion farmaceutica, proceso y uso en terapia
NO20080445L (no) Nye azetidinderivater som neurokininreseptorantagonister for behandling av gastrointestinale sykdommer
NO20080061L (no) Imidazolyl-pyrimidinforbindelser for anvendelse til behandling av proliferative lidelser
ECSP077277A (es) Derivados arilsulfonilestilbeno para tratamiento de insomnio y afecciones relacionadas
BRPI0918517B8 (pt) composto, composição farmacêutica, e, uso de um composto
ATE496918T1 (de) Als a2b-adenosinrezeptorantagonisten geeignete 5- phenyl-6-pyridin-4-yl-1,3-dihydro-2h-imidazoä4, - büpyridin-2-onderivate
ATE490958T1 (de) Als agonisten für den nikotinischen acetylcholinrezeptor geeignete azabicycloalkanderivate
ATE466842T1 (de) 3-substituierte pyridinderivate als h3- antagonisten

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees